You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
耀才團隊: 大市失去方向 市場轉炒新股
阿思達克 12-02 11:57
耀才證券研究部團隊稱,隔晚(12月1日)歐美股市全線向上,美國參議院兩黨小組公布規模達9,080億美元的經濟紓困計劃,加上輝瑞(PFE.US)與BioNTech(BNTX.US)周一正式向歐洲監管機構提交申請,希望當局能批准其研發的新冠肺炎疫苗,疫苗有望在年底前獲批,刺激道指最多飆444點,全日高見30,083點;標指盤中破頂見3,678點;納指盤中同樣破頂高見12,405點,升幅為三大指數之中最強。港股ADR變動不大,預料大市將會在10天線水平爭持。個股方面,京東健康(06618.HK)認購反應熱烈,獲公開發售超購逾420倍,以每股70.58元定價,為招股價區間上限。

從技術上看,恆指於上周以「大陰燭」從高位回落,指數跌穿10天線之支持,短期尋頂之勢頭將呈現變數,目前首個支持位亦退至20天線26,200點。此短期升浪以10月30日低開24,029點起,至11月25日高位27,040點計,累積升幅達3,011點,若調整黃金比率0.382,則指數將跌穿20天線,並回試25,900點。

(筆者為證監會持牌人)~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account